SYDNEY, April 9, 2014 /PRNewswire/ -- For the second year in a row, ide's innovative and world-class product design has been recognised at the 2014 Medical Design Excellence Awards (MDEA). The AtomoRapid™ HIV is one of three finalists in the In Vitro Diagnostic Products and Systems category of this year's MDEA, the Medtech industry's leading international awards.
AtomoRapid™ HIV is the world's first integrated rapid HIV blood test, offering a simple, reliable solution for diagnosing HIV in the field. The new device was launched in commercially in December 2013 and represents a breakthrough for convenient in-situ testing for the disease.
AtomoRapid™ HIV is currently marketed in South Africa by ide's product development partner Atomo Diagnostics. ide provided product design, engineering, and development services and continue to be involved in production and quality assurance for the device by manufacturing components as part of their ide Deliver service.
This is the second year in a row that ide have been recognised as 'Suppliers to a Finalist' in the MDEA, after the ResMed Pixi Pediatric Mask was shortlisted as a finalist in 2013.
ide Product Development Director, Richard Sokolov commented,
"ide helped found Atomo Diagnostics four years ago to create products that make blood collection and diagnostics simpler and more reliable outside of the laboratory. It's just tremendous that our first product has made such an impact. AtomoRapid™ HIV represents a huge breakthrough in HIV diagnosis and has been enthusiastically welcomed by clinicians in South Africa since launch. The Atomo Diagnostics / ide team has worked incredibly hard to make this happen and I'm so proud to see our efforts recognised."
"At ide we believe that with caring, creativity and grit, we can realise the hope we all have for our projects. Our journey with the AtomoRapid has really shown that this philosophy can lead to the launch of disruptive products and significant commercial success."
Winners of the 2014 Medical Design Excellence Awards will be announced in New York on 11 June.
